文献速递白血病造血干细胞移植与细胞治疗

达沙替尼两步诱导方案治疗成人费城染色体阳性急性淋巴细胞白血病

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

本研究评估达沙替尼为基础的两步诱导方案治疗成人Ph+ ALL,主要终点为3年无事件生存率。78例可评估患者中,第一步诱导后全部达完全缓解,第二步诱导后52.6%达MRD阴性。中位随访4.0年,3年EFS为66.2%,OS为80.5%,3年累积复发率和非复发死亡率分别为26.1%和7.8%。

要点

  • 达沙替尼两步诱导方案可提高Ph+ ALL患者的3年EFS至66.2%。
  • 第一步诱导后全部患者达CR,第二步诱导后52.6%达MRD阴性。
  • 74.4%患者可在第一次完全缓解期接受异基因造血干细胞移植。

核心结论

  • 达沙替尼为基础的两步诱导方案可改善成人Ph+ ALL患者的3年无事件生存率。

研究设计与样本

  • 本研究为评估达沙替尼为基础两步诱导方案的前瞻性研究,纳入78例可评估的成人Ph+ ALL患者,主要终点为3年无事件生存率。

主要发现

  • 所有78例可评估患者在第一诱导(达沙替尼联合泼尼松龙)后达到完全缓解或不完全完全缓解。
  • 52.6%的患者在第二诱导(达沙替尼联合强化化疗)后达到MRD阴性。
  • 中位随访4.0年,3年无事件生存率为66.2%(95% CI 54.4-75.5),总生存率为80.5%(95% CI 69.7-87.7)。
  • 从入组起3年累积复发率为26.1%,非复发死亡率为7.8%。

关键数值与推荐

  • 第一诱导方案为达沙替尼联合泼尼松龙,用于达到完全缓解。
  • 第二诱导方案为达沙替尼联合强化化疗,用于达到MRD阴性。
  • 对于达到完全缓解且有合适供者的患者,推荐在首次巩固(包括大剂量甲氨蝶呤)之后的巩固阶段进行异基因造血干细胞移植。
  • 移植前MRD阳性的患者被分配接受移植后预防性达沙替尼治疗。

临床怎么用

  • 达沙替尼为基础的两步诱导方案可作为成人Ph+ ALL的治疗选择,以提高无事件生存率。
  • 达到完全缓解后应评估供者情况,适合者推荐在巩固阶段进行异基因造血干细胞移植。
  • 移植前MRD阳性患者可考虑移植后预防性使用达沙替尼。

局限性

  • 非复发死亡率未报告。
  • 研究未报告样本量、P值等统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard treatment for adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, ∼40% of patients cannot undergo HSCT in their first complete remission (CR1) because of chemotherapy-related toxicities or relapse before HSCT or older age. In this study, we evaluated dasatinib-based 2-step induction with the primary end point of 3-year event-free survival (EFS). The first induction (IND1) was dasatinib plus prednisolone to achieve CR, and IND2 was dasatinib plus intensive chemotherapy to achieve minimal residual disease (MRD) negativity. For patients who achieved CR and had an appropriate donor, HSCT during a consolidation phase later than the first consolidation, which included high-dose methotrexate, was recommended. Patients with pretransplantation MRD positivity were assigned to receive prophylactic dasatinib after HSCT. All 78 eligible patients achieved CR or incomplete CR after IND1, and 52.6% achieved MRD negativity after IND2. Nonrelapse mortality (NRM) was not reported. T315I mutation was detected in all 4 hematological relapses before HSCT. Fifty-eight patients (74.4%) underwent HSCT in CR1, and 44 (75.9%) had negative pretransplantation MRD. At a median follow-up of 4.0 years, 3-year EFS and overall survival were 66.2% (95% confidence interval [CI], 54.4-75.5) and 80.5% (95% CI, 69.7-87.7), respectively. The cumulative incidence of relapse and NRM at 3 years from enrollment were 26.1% and 7.8%, respectively. Dasatinib-based 2-step induction was demonstrated to improve 3-year EFS in Ph+ ALL. This study was registered in the UMIN Clinical Trial Registry as #UMIN000012173.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 34516628. doi:10.1182/bloodadvances.2021004607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。